Download PDF
Fortschr Neurol Psychiatr 2020; 88(09): 552-557
DOI: 10.1055/a-1099-9380
Editorial

20 Jahre Experten Meeting Parkinson

Eine Tour d´Horizon durch die Welt der Parkinsonerkrankungen20th Experten Meeting Parkinson
› Further Information
    Permissions and Reprints

Zusammenfassung

Das Experten Meeting Parkinson ist ein Treffen führender deutschsprachiger Parkinsonexperten, das in wechselnder Besetzung seit 2000 stattfindet und mit dem jüngsten Treffen in Frankfurt 2019 sein 20-jähriges Jubiläum feierte.

Abstract

The Meeting of Parkinson Experts is a meeting of leading German-speaking Parkinson experts, which has been taking place in a changing line-up since 2000. Its 20th anniversary was celebrated with the latest meeting in Frankfurt 2019.

Schlüsselwörter

Experten Meeting - Parkinson - 20 Jahre

Key words

meeting of experts - Parkinson - 20th anniversary


Publication History

Received: 10 January 2020

Accepted: 11 January 2020

Article published online:
06 July 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Whone AL, Watts RL, Stoessl AJ. et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54 (Suppl. 1): 93-101.
    CrossrefPubMedGoogle Scholar
  • 2 Baas H. Dyskinesia in Parkinson’s disease. Pathophysiology and clinical risk factors. J Neurol 2000; 247 (Suppl. 4): IV12-IV16.
    CrossrefPubMedGoogle Scholar
  • 3 Müngersdorf M, Sommer U, Sommer M. et al. High-dose therapy with ropinirole in patients with Parkinson’s disease. J Neural Transm 2001; 108 (Suppl. 11): 1309-1317.
    CrossrefPubMedGoogle Scholar
  • 4 Weintraub D. Impulse control disorders in Parkinson’s disease: a 20-year odyssey. Mov Disord 2019; 34 (Suppl. 4): 447-452.
    CrossrefPubMedGoogle Scholar
  • 5 Jost WH, Braune S. Autonome Regulationsstörungen beim idiopathischen Parkinsonsyndrom. Akt Neurol 2001; 28 (Suppl. 3): S235-S241.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Krüger R. Genes in familial parkinsonism and their role in sporadic Parkinson’s disease. J Neurol 2004; 251 (Suppl. 6): VI/2-VI/6.
    CrossrefPubMedGoogle Scholar
  • 7 Junghanns S, Glöckler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004; 6 (Suppl. 6): VI/19-VI/23.
    PubMedGoogle Scholar
  • 8 Wüllner U, Buhmann C, Hilker R. et al. Ropinirole 24-hour Zukunft. Akt Neurol 2007; 34 (Suppl. 1): S18-S20.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Schapira AH. Ropinirole 24-hour extended release for Parkinson’s disease. Akt Neurol 2007; 34 (Suppl. 1): S15-S17.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Pahwa R, Stacy MA, Factor SA. et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68 (Suppl. 14): 1108-1115.
    CrossrefPubMedGoogle Scholar
  • 11 Reichmann H, Cooper J, Rolfe K. et al. Sleep duration and „on“ time during different periods of the day and night in patients with advanced Parkinson’s disease receiving adjunctive ropinirole prolonged release. Parkinsons Dis 2011; 2011: 354760. doi:10.4061/2011/354760. Epub 2011 May 11.
    CrossrefPubMedGoogle Scholar
  • 12 Jost WH, Buhmann C, Fuchs G. et al. Initial experience with ropinirole PR (prolonged release). J Neurol 2008; 255 (Suppl. 5): 60-63.
    CrossrefPubMedGoogle Scholar
  • 13 Van Camp G, Flamez A, Cosyns B. et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363 (Suppl. 9416): 1179-1183.
    CrossrefPubMedGoogle Scholar
  • 14 Reichmann H, Ehret R, Happe S. et al. Kardiale Fibrosen unter Dopaminagonisten – was gibt es Neues?. Akt Neurol 2007; 34 (Suppl. 1): 521-524.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Jost WH, Leupold CS. Grundlagen der Pflasterapplikation von Wirkstoffen beim Parkinson-Syndrom. Akt Neurol 2009; 36 (Suppl. 4): S288-S292.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Trenkwalder C, Kies B, Rudzinka M. et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26 (Suppl. 1): 90-99.
    CrossrefPubMedGoogle Scholar
  • 17 Respondek G, Decker S, Steinmeyer L. et al. Differentialdiagnosen der Parkinson-Krankheit: aktuelle Konsensuskriterien und Ausblicke. Fortschr Neurol Psychiat 2010; 78 (Suppl. 1): S8-S15.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Höglinger GU, Respondek G, Stamelou M. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 2017; 32 (Suppl. &): 853-864.
    CrossrefPubMedGoogle Scholar
  • 19 Antonini A, Jost WH. Duodentale levodopa and apomorphine infusion for motor complications in advanced Parkinson’s disease. Fortschr Neurol Psychiatr 2018; 86: S5-S9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Yilmaz R, Hopfner F, van Eimeren T. et al. Biomarkers of Parkinson’s disease: 20 years later. J Neural Transm 2019; 126 (Suppl. 7): 803-813.
    CrossrefPubMedGoogle Scholar
  • 21 Riederer P, Berg D, Casadei N. et al. α-Synuclein in Parkinson’s disease: causal or bystander?. J Neural Transm 2019; 126 (Suppl. 7): 815-840.
    CrossrefPubMedGoogle Scholar
  • 22 Braak H, Del Tredici K, Bratzke H. et al. Staging of the intracebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 2002; 249 (Suppl. 3): III/1-III/5.
    CrossrefPubMedGoogle Scholar